0.341

8.12% 0.0256

After Hours: .34 -0.001 -0.29%

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $0.341, with a volume of 825.35K. It is up +8.12% in the last 24 hours and down -42.01% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$0.3154

Open:

$0.302

24h Volume:

825.35K

Relative Volume:

1.36

Market Cap:

$16.49M

Revenue:

$1.38M

Net Income/Loss:

$-179.05M

P/E Ratio:

-0.048

EPS:

-7.11

Net Cash Flow:

$-155.03M

1W Performance:

-17.25%

1M Performance:

-42.01%

6M Performance:

-70.09%

1Y Performance:

-88.52%

1-Day Range:

$0.3001

$0.3441

1-Week Range:

$0.3001

$0.52

52-Week Range:

$0.3001

$4.17

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2024-11-12

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	0.341	16.49M	1.38M	-179.05M	-155.03M	-6.14
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Dec 17, 2024

Bioxcel therapeutics CEO sells shares worth $1,131 By Investing.com - Investing.com Australia

Dec 17, 2024

Bioxcel therapeutics' chief scientific officer sells $151 worth of stock By Investing.com - Investing.com Canada

Dec 17, 2024

Bioxcel therapeutics CFO Richard Steinhart sells $206 in stock - Investing.com India

Dec 17, 2024

Bioxcel therapeutics executive sells $153 in stock - Investing.com

Dec 17, 2024

Bioxcel therapeutics CEO sells shares worth $1,131 - Investing.com

Dec 17, 2024

Bioxcel therapeutics exec sells $58 in stock By Investing.com - Investing.com UK

Dec 17, 2024

Dec 16, 2024

BioXcel Therapeutics stock hits 52-week low at $0.35 - Investing.com India

Dec 16, 2024

Dec 05, 2024

BioXcel Therapeutics (STU:BX2) 5-Day RSI : 7.74 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

BioXcel Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada

Dec 05, 2024

Dec 04, 2024

BioXcel Therapeutics stock hits 52-week low at $0.4 - Investing.com India

Dec 04, 2024

Nov 25, 2024

BioXcel Therapeutics announces pricing of $7M public offering - MSN

Nov 25, 2024

Nov 23, 2024

BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia

Nov 23, 2024

Nov 22, 2024

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering - GlobeNewswire

Nov 22, 2024

BioXcel Therapeutics Announces $7M Public Offering at $0.48 Per Share with Warrants | BTAI Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

BioXcel Therapeutics amends credit agreement, issues new warrants - Investing.com

Nov 21, 2024

BioXcel Therapeutics amends credit agreement, issues new warrants By Investing.com - Investing.com Canada

Nov 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering - GlobeNewswire

Nov 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering - Benzinga

Nov 21, 2024

BioXcel Therapeutics Launches Public Offering to Fund Critical Clinical Trials | BTAI Stock News - StockTitan

Nov 21, 2024

Nov 20, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 18, 2024